Page last updated: 2024-10-28

guanfacine and Anxiety Neuroses

guanfacine has been researched along with Anxiety Neuroses in 5 studies

Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.

Research Excerpts

Excerpt	Relevance	Reference
"Youth aged 6-17 years with a primary diagnosis of GAD, SAD, and/or social anxiety disorder were treated with flexibly dosed GXR (1-6 mg daily, n = 62) or placebo (n = 21) for 12 weeks."	6.84	Extended Release Guanfacine in Pediatric Anxiety Disorders: A Pilot, Randomized, Placebo-Controlled Trial. ( Albano, AM; Compton, SN; Hamdani, M; Robertson, B; Rynn, MA; Strawn, JR, 2017)
"Youth aged 6-17 years with a primary diagnosis of GAD, SAD, and/or social anxiety disorder were treated with flexibly dosed GXR (1-6 mg daily, n = 62) or placebo (n = 21) for 12 weeks."	2.84	Extended Release Guanfacine in Pediatric Anxiety Disorders: A Pilot, Randomized, Placebo-Controlled Trial. ( Albano, AM; Compton, SN; Hamdani, M; Robertson, B; Rynn, MA; Strawn, JR, 2017)

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (20.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
de Groof, C	1
De La Marche, W	1
Danckaerts, M	1
Mattingly, GW	1
Anderson, RH	1
Strawn, JR	1
Compton, SN	1
Robertson, B	1
Albano, AM	1
Hamdani, M	1
Rynn, MA	1
Hollander, E	1
Newcorn, JH	1
Schulz, K	1
Harrison, M	1
DeBellis, MD	1
Udarbe, JK	1
Halperin, JM	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).[NCT01470469]			Phase 2	83 participants (Actual)	Interventional	2012-01-04	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Diastolic Blood Pressure at Up to 12 Weeks

(NCT01470469)
Timeframe: Baseline and up to 12 weeks

Intervention	mmHg (Mean)
PLACEBO	0.9
SPD503	-1.3

Change From Baseline in ECG QTcF Interval at up to 12 Weeks

The QT interval is the time from the start of the Q wave to the end of the T wave. It is a portion of the ECG tracing that represents the time taken for ventricular depolarisation and repolarisation. The QTcF includes a correction factor to help account for changes in heart rate. (NCT01470469)
Timeframe: Baseline and up to 12 weeks

Intervention	msec (Mean)
PLACEBO	0.3
SPD503	4.1

Change From Baseline in Electrocardiogram (ECG) QRS Interval at up to 12 Weeks

QRS complex is a portion of the ECG tracing that represents depolarization of the ventricular myocardium. (NCT01470469)
Timeframe: Baseline and up to 12 weeks

Intervention	msec (Mean)
PLACEBO	0.7
SPD503	0.1

Change From Baseline in Height at up to 12 Weeks

(NCT01470469)
Timeframe: Baseline and up to 12 weeks

Intervention	cm (Mean)
PLACEBO	0.5
SPD503	1.0

Change From Baseline in Pulse Rate at Up to 12 Weeks

(NCT01470469)
Timeframe: Baseline and up to 12 weeks

Intervention	beats/min (Mean)
PLACEBO	-0.5
SPD503	-1.8

Change From Baseline in Systolic Blood Pressure at Up to 12 Weeks

(NCT01470469)
Timeframe: Baseline and up to 12 weeks

Intervention	mmHg (Mean)
PLACEBO	-1.7
SPD503	-2.3

Change From Baseline in Weight at up to 12 Weeks

(NCT01470469)
Timeframe: Baseline and up to 12 weeks

Intervention	kg (Mean)
PLACEBO	0.7
SPD503	1.3

Reviews

3 reviews available for guanfacine and Anxiety Neuroses

Article	Year
[Effectiveness of guanfacin on comorbid disorders in children and adolescents with adhd: a systematic literature review]. Tijdschrift voor psychiatrie, 2019, Volume: 61, Issue:12 Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Anxiety Disorders; Attention Deficit Disorder with	2019
Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems. CNS spectrums, 2016, Volume: 21, Issue:S1 Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Anxiety Disorders; Atomoxetine H	2016
Alpha 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children. Pediatric clinics of North America, 1998, Volume: 45, Issue:5 Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Anxiety Disorders; Attention Defici	1998

Trials

1 trial available for guanfacine and Anxiety Neuroses

Article	Year
Extended Release Guanfacine in Pediatric Anxiety Disorders: A Pilot, Randomized, Placebo-Controlled Trial. Journal of child and adolescent psychopharmacology, 2017, Volume: 27, Issue:1 Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Anxiety Disorders; Anxiety, Separation; Child; Del	2017

Other Studies

1 other study available for guanfacine and Anxiety Neuroses

Article	Year
Treatment response and redefining diagnostic boundaries. CNS spectrums, 2008, Volume: 13, Issue:12 Topics: Adrenergic alpha-Agonists; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Depress	2008